Royal Bank Of Canada Cytom X Therapeutics, Inc. Transaction History

Royal Bank Of Canada

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.21 - $5.13 $300 - $1,272	248 New	248 $0
Q4 2023 Feb 14, 2024	BUY	$1.07 - $1.55 $853 - $1,236	798 New	798 $1,000
Q2 2023 Aug 14, 2023	BUY	$1.41 - $1.92 $541 - $737	384 Added 384.0%	484 $0
Q4 2022 Feb 14, 2023	SELL	$1.19 - $1.91 $210 - $338	-177 Reduced 63.9%	100 $0
Q3 2022 Nov 14, 2022	BUY	$1.23 - $1.97 $217 - $348	177 Added 177.0%	277 $0
Q2 2022 Aug 15, 2022	SELL	$1.53 - $2.89 $6,097 - $11,516	-3,985 Reduced 97.55%	100 $0
Q1 2022 May 16, 2022	SELL	$2.67 - $4.68 $29,175 - $51,138	-10,927 Reduced 72.79%	4,085 $11,000
Q4 2021 Feb 14, 2022	BUY	$3.87 - $7.39 $32,314 - $61,706	8,350 Added 125.34%	15,012 $64,000
Q3 2021 Nov 15, 2021	BUY	$4.32 - $6.43 $4,847 - $7,214	1,122 Added 20.25%	6,662 $35,000
Q2 2021 Aug 16, 2021	BUY	$6.33 - $9.91 $35,068 - $54,901	5,540 New	5,540 $35,000

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.